Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance

BACKGROUND: In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahin, Özgür, Fröhlich, Holger, Löbke, Christian, Korf, Ulrike, Burmester, Sara, Majety, Meher, Mattern, Jens, Schupp, Ingo, Chaouiya, Claudine, Thieffry, Denis, Poustka, Annemarie, Wiemann, Stefan, Beissbarth, Tim, Arlt, Dorit
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652436/
https://www.ncbi.nlm.nih.gov/pubmed/19118495
http://dx.doi.org/10.1186/1752-0509-3-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652436/
https://www.ncbi.nlm.nih.gov/pubmed/19118495
http://dx.doi.org/10.1186/1752-0509-3-1

Ejemplares similares